← Leaderboards
Akhilesh K Sista
New York University School Of Medicine
$2,379,135
Attributed
$4,535,743
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2019–23$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,535,743 · 3
By mechanism
UG3$2,190,267 · 1
UH3$2,122,950 · 1
U34$222,526 · 1
Top collaborators
- Sunil V Rao2 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Keng-Yen Huang$4,429,307
- Antoinette M Schoenthaler$12,165,127
- Paolo Cassano$3,422,329
- Dan Vlad Iosifescu$5,888,556
- Devin M Mann$15,152,649
Others in their field
Other Emerging Leaders on “Fibrinolytic Agents”
- Christina U Lorentz · Aronora, Inc.$4,654,444
- Kenneth B. Bader · University Of Chicago$4,178,329
- Sunil V Rao · Va Puget Sound Healthcare System$4,012,769
- Shahid Nimjee · Basking Biosciences$3,606,480
- Brian Garriock Firth · Thrombolex, Inc.$2,964,550
- Aditya S Pandey · University Of Michigan At Ann Arbor$2,912,936
Research focus
Fibrinolytic AgentsPeripheralDoseExercise CapacityInnovationOptimal TreatmentsClinical TrialsDeteriorationConsultationsExcisionGrantHemorrhageBlood PressureNational Heart, Lung, And Blood InstituteAcuteCathetersCostDangerousnessAnticoagulant TherapyChronicCoagulation ProcessEnrollmentAnticoagulationPrevent
Grant awards (3)
1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial)$2,122,950
UH3 · FY2023 · HL
1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial)$2,190,267
UG3 · FY2022 · HL
Late Phase Clinical Trial Design and Planning for Pulmonary Embolism - Thrombus Removal with Adjunctive Catheter-Directed Therapy (PE-TRACT)$222,526
U34 · FY2019 · HL · contact PI